Officials with the FDA have expanded the use of Melinta Therapeutics’ delafloxacin (Baxdela) to include treatment of adult patients with community-acquired bacterial pneumonia caused by designated susceptible bacteria, but the drug’s availability will be delayed for this new indication.
A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.
The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.
The NFID released data that revealed only 52% of adults in the country plan to get vaccinated against the flu this season.
Continuing education to improving adult pneumococcal immunization rates.
Meningitis is a deadly condition that affects up to 1 million people per year globally.1
A binational team of investigators at the University of California, Davis, has conducted the first comprehensive study to examine the risk factors for Rocky Mountain spotted fever in Mexicali, Mexico. They found that citywide, just 1 in 1000 ticks was infected with the disease, but in certain neighborhoods, about 1 in 10 ticks was infected.
Brown Bagging is an essential educational and safety tool for helping treat community-acquired pneumonia.
The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.
A triad of techniques can reduce the likelihood of infection, and pharmacy teams can help patients with all of them.
The CDC has declared immunizations one of the greatest health achievements of the 20th century, but vaccination rates among adults remain suboptimal.
Officials with the FDA have approved Xellia Pharmaceuticals’ Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag, according to the company.
HIV-positive patients with hepatocellular carcinoma had an adjusted 24% increased hazard of death compared to their HIV-negative peers.
People who inject drugs may not accurately self-report HIV and antiretroviral drug status when entering an HIV prevention study.
Community-acquired pneumonia is a major cause of mortality and morbidity among patients with HIV.
Researches seeking to eliminate HIV are close enough to see the finish line, but with no idea how far away they are from a cure.
Foreign-born black women aren’t benefiting from HIV prevention programs at the same rates as other women.
The overuse of antimicrobials is associated with antimicrobial resistance, which is now a global crisis.
New research underscores the value of review by an ID physician, nurse, or pharmacist before starting OPAT.
The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.
Stigma may cause undiagnosed individuals with HIV to go unidentified and fail to get quality care and treatment.
FDA officials have approved omadacycline (Nuzyra, Paratek), a modernized tetracycline, to treat adults with acute skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Inconsistency of insurance policy coverage, unaffordability, and difficulty accessing vaccine providers were found to be key barriers for adult immunization in a recent study by UCLA Center for Health Policy researchers.
Financial modeling tool shows research and development lacking of new vaccine candidates for HIV, tuberculosis, and malaria.
